Sutro Biopharma Announces First Patient Dosed in Phase 1 Trial of STRO-006, a Next-Generation ITGB6-Targeting ADC, in Advanced Solid Tumors
Sutro Biopharma dosed the first patient in a Phase 1 trial of STRO-006, its ITGB6-targeting exatecan ADC with a drug-to-antibody ratio of 8, in advanced solid tumors. STRO-006 is the company's second wholly-owned ADC to enter the clinic in under a year; the open-label multicenter dose-escalation trial starts at 1.5 mg/kg, supported by tolerability in non-human primates at doses up to 30 mg/kg.
Key figures
- Drug Name
- STRO-006
- Phase Of Trial
- Phase 1
- Starting dose
- 1.5 mg/kg
- Nhp tolerance dose
- up to 30 mg/kg
- Drug antibody ratio
- 8
- Initial data timing
- second half of 2027
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.